Abstract
Introduction Atrial fibrillation is the most prevalent cardiac arrhythmia, significantly increasing the risk of stroke and heart failure in non-valvular AF, percutaneous coronary intervention and transcatheter aortic valve implantation patients. Warfarin has long been the standard treatment, but with multiple limitations. Edoxaban has shown to affect bleeding outcomes. This study provides a very detailed outlook comparing both drugs in myriad of scenarios. Methods This study involved a thorough review of PubMed, Medline, Embase and ClinicalTrials.gov from Jan 2014-Oct 2024. Outcomes included Stroke and systemic embolism (SSE), major adverse cardiac events (MACE), all-cause mortality, clinically relevant non-major bleeding (CRNM) and major bleeding (MB). Data pooled using hazard ratio (HR) with 95% confidence intervals (CI) using random-effects with statistical significance at <0.05. STATA v17 was used. Risk of bias was assessed using RoB v2 tool & GRADE assessment. Subgroup analysis and Egger's test were utilized to address high heterogeneity and publication bias, respectively. PRISMA guidelines were thoroughly followed. This study is registered on PROSPERO (CRD420250648890). Results Five clinical trials comprising of 26,832 participants were included in our comprehensive analysis. MACE showed edoxaban to be marginally superior to warfarin (HR 0.90, 95% CI 0.83-0.97, p = 0.01), renal clearance of ?80 resonated a similar result. VKA performed better in reducing MACE when CHA2DS2VASc score was ?4.0. Edoxaban had a more significant effect in decreasing the risk of SSE. In CRNM, VKA had a far better effect in patients with age of <65 years and those with normal renal clearance had significant group differences. Conclusions Edoxaban remains to hold a solid ground in multiple key outcomes while essential role of warfarin in significant scenarios such as in patients with higher CHADVASc score, previous MI, older age and those with heart failure cannot be ruled out. Further studies to confirm findings.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
N/A
Funding Statement
No funding received.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The datasets generated and/or analyzed during the current study are available from the corresponding author upon reasonable request.
